COVID-19 Vaccination Services for Businesses and Communities
As the coronavirus vaccine rollout continues to evolve, businesses and community organizations want to offer on-location COVID-19 vaccinations to employees. Vaccine availability and administration regulations vary from state to state, so contact us to discuss your organization’s suitability for on-site COVID-19 vaccinations.
Choose the level of support your business or community organization needs for a successful vaccination program.
COVID-19 Vaccination Program Design and Support
Providing comprehensive support from planning to administration, Remote Medical International® can deliver the necessary guidance and personnel for a successful on-site vaccination program.
- Consulting: Guidance to make your vaccination program a success.
- Logistics and Supply: Experienced in moving equipment and supplies globally; from PPE to equipment to staffing, we have you covered.
- Staffing: Long history of deploying qualified healthcare professionals quickly to any location.
- Scheduling and Tracking: Patient scheduling and dosage tracking.
Business and Community COVID-19 Vaccine Staffing Services
Already have a vaccine administration plan and just need the medical staff to execute it? We can get the appropriate staff to your location quickly, including:
- Vaccine administrators
- Medical support personnel
- Clerical support personnel
- Keep employees healthy
- Minimize time away from work
- Improve employee morale
FAQs for Vaccinating Employees
- High-risk individuals at increased risk for severe illness (including those with underlying medical conditions and people over 65).
- Essential workers and critical infrastructure, which is generally defined as, but not limited to, medical and healthcare, telecommunications, information technology systems, defense, food and agriculture, transportation and logistics, energy, water and wastewater, and law enforcement.
- Geographies with a high prevalence and spread of COVID-19.
Following this, the goal has been to have the vaccine available to every American as quickly as possible, and estimates for this goal are projected to be around mid/late summer to early fall.
So if your organization is defined as “critical infrastructure” you will likely be able to vaccinate your workforce within the next few months. If not, you’ll have to wait a bit longer.
In the US it’s free, but you will have to wait your turn. The vaccine is being distributed at no cost to Americans and cannot be purchased or resold. Other global regions may have different parameters. Contact us to talk about setting up a COVID-19 vaccine program outside of the US.
The US Federal Government has begun distributing the first tranche of COVID-19 vaccines to state governments and through the federal pharmacy partnership with private companies for administration to citizens.
In this initial phase, the states have determined the first-round recipients, generally following the federal prioritization guidance to include healthcare personnel, essential workers, adults 65+, and with underlying medical conditions.
The Federal Government continues to work with state, local, tribal and territorial governments to fill gaps that local health officials have identified in the administration of vaccines. It is anticipated that there will be distribution of vaccines for large organizations’ occupational health settings but guidance or details have yet to be defined.
Other countries are approaching distribution differently. Contact us to learn more about vaccine distribution in your region.
Should I continue with testing, screening, and other preventative measures once the vaccine is available?
Yes. A robust COVID-19 management program will remain important in conjunction with a vaccine program. Many unknown variables are still surrounding the distribution process, citizen take-up rate (vaccine hesitancy), and reinfection rates after receiving the vaccine. Additionally, all organizations should continue to follow country, state, and local regulations.
Initial data from late-stage clinical trials for Pfizer and Moderna shows a high efficacy rate at 94-95%.